What If an Ingredient Could Extend Your Skin's Biological Lifespan?

📅 April 27, 2026👤 Restorative and Medical Skincare Researcher Simon Finch⏱ 14 min read

What If an Ingredient Could Extend Your Skin's Biological Lifespan?

We talk about anti-aging as if aging were an enemy to be defeated. But aging is not a disease. It is a biological process governed by specific molecular mechanisms — collectively known as the Hallmarks of Aging. First proposed by López-Otín and colleagues in 2013 and updated in 2023, this framework identifies the fundamental cellular and molecular processes that drive age-related decline across every tissue in the body, including the skin.

For women over 60, these processes are no longer theoretical. They are visible in the mirror: thinner skin, slower wound healing, loss of elasticity, increased fragility, uneven pigmentation. These are not cosmetic problems. They are the outward manifestations of decades of molecular wear and tear at the deepest levels of your skin cells.

PDRN (polydeoxyribonucleotide) touches more of these hallmarks than any other topical ingredient currently available. This is not marketing hype. It is a direct consequence of the fact that nucleotide metabolism sits at the centre of multiple aging pathways. When you provide skin cells with the raw molecular building blocks they need to repair their own DNA, maintain their telomeres, sustain their mitochondria, and regulate their gene expression, you are not just treating symptoms — you are addressing root causes.

Understanding the Hallmarks of Aging Framework

Before we examine how PDRN interacts with specific aging pathways, it is worth understanding what the Hallmarks of Aging actually are and why they matter for skin. The framework, developed by Carlos López-Otín and colleagues at the Universidad de Oviedo, organises the complex biology of aging into discrete, measurable categories. The original 2013 paper identified nine hallmarks; the 2023 update expanded these to twelve, reflecting advances in our understanding of the aging process.

The twelve hallmarks are: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, dysbiosis, and mechanical stiffness of the extracellular matrix.

Each hallmark is defined by three criteria: (1) it manifests during normal aging, (2) experimentally aggravating it accelerates aging, and (3) experimentally ameliorating it slows aging. Not every cosmetic ingredient can meet even the first criterion. PDRN meets all three for multiple hallmarks simultaneously.

Why does PDRN have such broad effects? The answer lies in the central role of nucleotides — the molecular building blocks of DNA and RNA — in nearly every aspect of cellular maintenance. Without an adequate supply of deoxyribonucleotide triphosphates (dNTPs), cells cannot repair their DNA, maintain their telomeres, sustain mitochondrial function, or regulate gene expression through epigenetic mechanisms. PDRN, when applied topically, is broken down into these nucleotides and absorbed by skin cells, replenishing pools that become depleted with age.

Research by Kim and colleagues (2023) demonstrated that twice-daily application of topical PDRN significantly improved skin elasticity, hydration, and density in a cohort of postmenopausal women over a 12-week period. The improvements were not merely cosmetic. Ultrasound measurements showed increased dermal thickness, and biopsies revealed increased collagen synthesis — evidence that fundamental tissue structure was being restored.

Hallmark 1: Genomic Instability — The Accumulation of DNA Damage

Genomic instability refers to the progressive accumulation of DNA damage that occurs in all cells over time. Every cell in your body sustains tens of thousands of DNA damage events every single day. These lesions come from multiple sources: ultraviolet radiation from sunlight, oxidative stress from normal metabolism, environmental toxins, and even the spontaneous depurination of DNA bases.

A single human fibroblast sustains approximately 10,000 DNA damage events per day. The repair of each lesion requires a supply of deoxyribonucleotide triphosphates (dNTPs). When dNTP pools are insufficient, repair slows and unrepaired damage accumulates. This accumulation drives everything from mutations in critical genes to the activation of cell death pathways.

The Repair Machinery: Base Excision Repair and Nucleotide Excision Repair

DNA repair is not a single process but a coordinated network of pathways, each specialised for different types of damage. The two most relevant pathways for skin aging are base excision repair (BER) and nucleotide excision repair (NER).

BER handles small, non-helix-distorting lesions such as those caused by oxidative stress — the most common form of DNA damage in aged skin. During BER, a damaged base is removed by a DNA glycosylase enzyme, the resulting abasic site is cleaved, and a patch of one to ten nucleotides is synthesised to fill the gap. This gap-filling step requires dNTPs. Without them, the repair is incomplete.

NER handles larger, helix-distorting lesions such as those caused by UV radiation. This pathway removes a segment of approximately 24–32 nucleotides surrounding the damage and resynthesises the entire stretch. The nucleotide requirement for NER is therefore substantially greater than for BER, making it even more dependent on adequate dNTP pools.

In aged skin, dNTP pools decline significantly. Kim and colleagues (2022) demonstrated that the activity of the nucleotide salvage pathway — the primary route by which cells recycle nucleotides from degraded DNA — decreases by approximately 40% in aged human dermal fibroblasts compared with young fibroblasts. This means that older skin cells have a reduced intrinsic capacity to maintain their dNTP pools, leaving them vulnerable to accumulating DNA damage.

How PDRN Replenishes dNTP Pools

PDRN is a mixture of deoxyribonucleotides extracted from salmon sperm cells. When applied topically, it is broken down by cellular enzymes called nucleotidases into individual deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxycytidine, and thymidine). These are then imported into cells via nucleoside transporters and converted back into dNTPs through the salvage pathway.

Importantly, the expression of equilibrative nucleoside transporters (ENTs), which facilitate the uptake of nucleosides into cells, changes with age. Research by Roh and colleagues (2020) found that ENT expression is downregulated in aged human skin, which may contribute to the reduced dNTP pools observed in older fibroblasts. However, the same study demonstrated that topical application of PDRN can overcome this limitation by providing a sufficiently high concentration gradient to drive nucleoside uptake even through reduced transporter density.

Once inside the cell, the nucleosides are phosphorylated by salvage pathway enzymes — adenosine kinase, deoxycytidine kinase, thymidine kinase — to form dNTPs. This process bypasses the energetically expensive de novo synthesis pathway, meaning that PDRN provides nucleotides to cells that may no longer have the metabolic capacity to produce them from scratch.

Clinical evidence supports this mechanism. Chung and colleagues (2022) conducted a randomised controlled trial showing that topical PDRN applied twice daily for 12 weeks significantly reduced markers of DNA damage in skin biopsies from postmenopausal women, as measured by reduced 8-hydroxy-2'-deoxyguanosine levels — a standard biomarker of oxidative DNA damage.

Hallmark 2: Telomere Attrition — The Chromosomal Clock

Telomeres are the protective caps at the ends of your chromosomes. They consist of repeated sequences of DNA — TTAGGG in humans — that shorten with each cell division. Think of them as the plastic tips on shoelaces: without them, the chromosome ends would fray and fuse, causing genomic chaos.

Telomere shortening is a normal consequence of cell division because DNA polymerase cannot replicate the very end of a chromosome — a phenomenon known as the end-replication problem. With each division, telomeres shorten by approximately 50–100 base pairs. When they become critically short, the cell enters senescence or undergoes apoptosis.

Telomerase, the enzyme that can extend telomeres, is active in stem cells and germ cells but is expressed at very low levels in most somatic cells — including skin fibroblasts and keratinocytes. However, even the minimal telomerase activity present in skin cells can contribute to telomere maintenance when provided with adequate nucleotide substrates.

The Nucleotide Limitation of Telomerase

Telomerase is a reverse transcriptase that adds telomeric repeats to chromosome ends using its own RNA template. Each round of telomere elongation requires the addition of six nucleotides (TTAGGG). The enzyme must have a ready supply of dTTP, dATP, and dGTP — the three nucleotides needed for the telomeric repeat — to function.

In aged cells where dNTP pools are depleted, telomerase activity is constrained not by the amount of enzyme present but by the availability of its substrates. This is a crucial distinction. If the pool of dTTP is low, telomerase cannot add the thymidine residues needed to extend the telomere, regardless of how much enzyme is present.

By replenishing dNTP pools, PDRN removes this substrate limitation. The nucleotides provided through PDRN are exactly those required for telomere maintenance: the salvage pathway from PDRN-derived thymidine produces dTTP, while deoxyadenosine and deoxyguanosine from PDRN are converted to dATP and dGTP respectively.

The effect of PDRN on telomere length in skin cells has not yet been directly measured in human clinical trials — this is technically challenging because telomere length changes slowly — but the mechanistic rationale is solid. By ensuring that telomerase and other telomere maintenance proteins have the substrates they need, PDRN may help slow the rate of telomere attrition in skin cells.

Hallmark 3: Epigenetic Alterations — The Information Layer Above DNA

Epigenetics refers to heritable changes in gene expression that do not involve changes to the DNA sequence itself. The two most well-studied epigenetic mechanisms are DNA methylation and histone modification. Together, they determine which genes are active and which are silenced in any given cell.

With age, the epigenetic landscape of skin cells changes dramatically. Global DNA methylation decreases, while specific regions — particularly those associated with developmental and aging genes — become hypermethylated. These changes alter the expression of genes involved in collagen production, antioxidant defence, DNA repair, and cell cycle regulation.

The One-Carbon Metabolism Connection

DNA methylation is carried out by DNA methyltransferase enzymes that transfer a methyl group from S-adenosylmethionine (SAM) to cytosine bases in CpG dinucleotides. SAM is produced from methionine through the one-carbon metabolism cycle, which is intimately connected to nucleotide metabolism.

The key link is through the folate cycle. Tetrahydrofolate (THF) derivatives carry one-carbon units that are used in both nucleotide synthesis (for purine and thymidine production) and in the production of SAM. The salvage pathway — through which PDRN-derived nucleotides enter cellular metabolism — feeds into this cycle by providing the nucleotide intermediates that regulate its flux.

When cells are deficient in nucleotides, the one-carbon cycle shifts toward nucleotide production at the expense of SAM synthesis. This means that skin cells with depleted dNTP pools may have reduced capacity for DNA methylation, contributing to the epigenetic drift observed in aging.

By providing pre-formed nucleotides, PDRN relieves the demand on the one-carbon cycle for nucleotide synthesis, allowing more flux toward SAM production. This may help maintain normal DNA methylation patterns and slow the epigenetic changes associated with aging.

Histone Modifications and NAD+

Histone modifications — the addition or removal of acetyl, methyl, and other groups from histone proteins — represent another layer of epigenetic regulation. Sirtuins, a family of NAD+-dependent deacetylases, play a critical role in histone deacetylation and have been linked to longevity across species.

Sirtuin activity declines with age, partly due to declining NAD+ levels. While PDRN does not directly boost NAD+ (as nicotinamide riboside or NMN would), the maintenance of healthy mitochondria through PDRN's effects on mtDNA repair helps preserve cellular NAD+ levels indirectly. Mitochondria are central to NAD+ homeostasis, and cells with dysfunctional mitochondria show accelerated NAD+ decline.

Hallmark 4: Mitochondrial Dysfunction — The Cellular Power Failure

Mitochondria are the energy-producing organelles of cells. They convert nutrients into ATP through oxidative phosphorylation (OXPHOS), a process that requires the coordinated function of five protein complexes embedded in the inner mitochondrial membrane. Thirteen of these proteins are encoded by mitochondrial DNA (mtDNA), a small circular genome that is particularly vulnerable to damage.

Why Mitochondrial DNA Is Especially Vulnerable

Mitochondrial DNA is more susceptible to damage than nuclear DNA for several reasons. First, it is located close to the electron transport chain, where reactive oxygen species (ROS) are produced as byproducts of OXPHOS. Second, mtDNA lacks the protective histone packaging that shields nuclear DNA. Third, mtDNA repair pathways are less robust than those in the nucleus, relying primarily on base excision repair with limited capacity for other repair mechanisms.

Each mitochondrion contains multiple copies of mtDNA. When damage accumulates in enough copies, the mitochondrion cannot produce the proteins needed for OXPHOS, and ATP production declines. Cells compensate by increasing mitochondrial biogenesis, but this creates a vicious cycle: more mitochondria produce more ROS, which damage more mtDNA.

The decline in mitochondrial function with age is well-documented. In skin fibroblasts from older donors, ATP production is reduced by 30–50% compared with young donors. This energy deficit affects every ATP-dependent cellular process, including collagen synthesis, DNA repair, and cell migration.

PDRN Supports mtDNA Repair Through Mitochondrial dNTP Pools

Mitochondria maintain their own dNTP pools, separate from the nuclear pool, through dedicated pathways. The mitochondrial dNTP pool is generated primarily through the salvage pathway mediated by deoxyguanosine kinase (dGK) and thymidine kinase 2 (TK2).

When PDRN-derived nucleosides enter the cell, they are available for import into mitochondria via the mitochondrial nucleoside transporter system. Inside the mitochondrial matrix, they are phosphorylated by dGK and TK2 to produce the dNTPs needed for mtDNA repair.

Research by Lee and colleagues (2021) demonstrated that mitochondrial dNTP pools decline with age in human skin fibroblasts, correlating with increased mtDNA damage and reduced OXPHOS capacity. PDRN treatment in cell culture models reversed this decline and restored mitochondrial membrane potential — a key indicator of mitochondrial health.

The clinical relevance is significant. Skin cells with healthy mitochondria can produce more ATP, which means more energy for collagen synthesis, more capacity for DNA repair, and more effective antioxidant defence. This creates a positive feedback loop: better mitochondrial function means more energy for cellular maintenance, which means better mitochondrial function.

Hallmark 5: Cellular Senescence — When Cells Stop Dividing

Cellular senescence is a state of irreversible cell cycle arrest. When a cell becomes senescent, it stops dividing but does not die. Instead, it remains metabolically active and secretes a complex mixture of inflammatory cytokines, growth factors, matrix metalloproteinases, and ROS — collectively known as the senescence-associated secretory phenotype (SASP).

Senescent cells accumulate in aged tissues, including the skin. They contribute to aging through two mechanisms: (1) the loss of proliferative capacity means fewer cells are available for tissue maintenance and repair, and (2) the SASP creates a pro-inflammatory microenvironment that damages surrounding cells and degrades the extracellular matrix.

The DNA Damage-Senescence Connection

Senescence is triggered primarily by persistent DNA damage signalling. When a cell accumulates DNA damage that cannot be adequately repaired, the DNA damage response (DDR) activates two key tumour suppressor pathways: the p53/p21 axis and the p16INK4a/Rb axis. Both pathways converge on the inhibition of cyclin-dependent kinases (CDKs) that drive cell cycle progression.

The p53 pathway is activated by the upstream kinases ATM and ATR, which detect DNA double-strand breaks and replication stress respectively. Activated p53 upregulates p21, a CDK inhibitor that blocks the G1/S transition. If the damage is not resolved, p21 levels remain high and the cell enters a state of prolonged cell cycle arrest.

The p16INK4a/Rb pathway operates in parallel. p16INK4a inhibits CDK4 and CDK6, preventing the phosphorylation of retinoblastoma protein (Rb). Hypophosphorylated Rb represses E2F target genes needed for S-phase entry, producing a more stable arrest than p53 alone.

PDRN may delay the onset of senescence by reducing the burden of unrepaired DNA damage. When cells have adequate dNTP pools for efficient DNA repair, fewer damage events persist long enough to trigger the DDR. This means fewer cells reach the threshold of persistent damage that initiates senescence.

PDRN and the Senescence-Associated Secretory Phenotype

Even in cells that have already become senescent, PDRN may attenuate the most harmful aspect of senescence: the SASP. The A2A adenosine receptor, which is activated by adenosine generated from the breakdown of PDRN, has anti-inflammatory effects that may suppress SASP factor production.

Adenosine signalling through the A2A receptor activates adenylyl cyclase, raising intracellular cAMP levels. cAMP activates protein kinase A (PKA), which phosphorylates and inhibits the transcription factor NF-κB — the master regulator of inflammatory gene expression. Since many SASP factors (including IL-6, IL-8, and MMPs) are NF-κB target genes, inhibition of NF-κB by adenosine signalling can reduce SASP output.

Lee and colleagues (2021) mapped the expression of adenosine receptors in aged human skin and found that the A2A receptor is expressed on both fibroblasts and keratinocytes, with expression levels that change with age. The preservation of A2A receptor expression in aged skin suggests that the anti-inflammatory benefits of PDRN-derived adenosine signalling are available throughout the postmenopausal period.

This dual mechanism — reducing the initiation of senescence through DNA repair support and attenuating the SASP of existing senescent cells through adenosine signalling — gives PDRN a unique position among ingredients targeting cellular aging.

Hallmark 6: Loss of Proteostasis — The Protein Folding Crisis

The sixth hallmark of aging, loss of proteostasis, refers to the progressive failure of cells to maintain proper protein folding and degradation. Aged cells accumulate misfolded and aggregated proteins, which impair cellular function and activate stress responses.

While PDRN does not directly modulate protein folding or the proteasome, its effects on cellular energy status have indirect benefits for proteostasis. ATP is required for the function of molecular chaperones (such as Hsp70 and Hsp90) that assist protein folding, as well as for the ubiquitin-proteasome system that degrades misfolded proteins. By supporting mitochondrial function and ATP production, PDRN may help maintain the energy-dependent machinery of proteostasis in aged skin cells.

Furthermore, the nucleotides provided by PDRN can support the expression of heat shock proteins and other stress response factors through their role in RNA synthesis. While this is a secondary mechanism, it contributes to the overall pro-survival environment created by PDRN in aged cells.

Hallmark 7: Altered Intercellular Communication

With age, the communication between skin cells changes significantly. Fibroblasts produce less collagen and more matrix metalloproteinases (MMPs). Keratinocytes produce fewer growth factors. Melanocytes produce uneven pigment. Immune cells in the skin become chronically activated. These changes are driven partly by cell-intrinsic aging and partly by age-related changes in the signalling molecules that cells use to communicate.

PDRN influences intercellular communication through adenosine-mediated signalling. Adenosine, released from the breakdown of PDRN, acts as a paracrine signalling molecule that can influence the behaviour of surrounding cells. Through the A2A receptor, adenosine stimulates the expression of growth factors including vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-β), both of which play important roles in maintaining skin structure and function.

TGF-β signalling is particularly important for skin health. TGF-β stimulates fibroblasts to produce collagen and elastin, while inhibiting the production of MMPs that degrade the extracellular matrix. The decline in TGF-β signalling with age is a major contributor to dermal atrophy — the thinning of the skin that occurs in postmenopausal women.

By stimulating TGF-β expression through the A2A receptor, PDRN may help restore the intercellular signalling balance that is lost with age, promoting matrix synthesis over matrix degradation.

What This Means for Your Skin at 60+

The practical implications of PDRN's effects on the hallmarks of aging are significant. When you apply a PDRN serum consistently over weeks and months, you are not simply hydrating the skin surface or stimulating collagen production through irritation. You are providing your skin cells with the molecular tools they need to maintain themselves at every level: from the integrity of their DNA to the function of their mitochondria to the regulation of their gene expression.

The clinical trial data supports this. Kafi and colleagues (2007) demonstrated that retinol — the gold standard vitamin A ingredient — improved the appearance of aged skin by stimulating new collagen synthesis. But retinol works through a fundamentally different mechanism: it binds to nuclear retinoic acid receptors to change gene expression. PDRN works at a more fundamental level, providing the raw materials that cells need to execute their own maintenance programmes.

Quan and Fisher (2015) described the age-related changes in the dermal extracellular matrix microenvironment, emphasising that the loss of collagen and elastin in aged skin is not simply a matter of reduced synthesis but also of increased degradation. PDRN's effects on genomic stability and cellular senescence help address both sides of this equation: supporting the cells that produce matrix components while reducing the inflammatory signalling that drives matrix degradation.

Varani and colleagues (2006) demonstrated that fibroblasts from aged skin are not inherently defective — they are capable of producing collagen at levels comparable to young fibroblasts when provided with the appropriate signals. This finding underscores the potential of interventions like PDRN: rather than trying to override cellular programmes with high-dose retinoids or growth factors, PDRN simply supplies what the cells need to do what they already know how to do.

Building a Longevity-Focused Skincare Protocol

How should a woman over 60 incorporate PDRN into a protocol aimed at maximising skin longevity? Based on the mechanistic evidence and clinical trial data, here are evidence-informed recommendations:

Consistency matters more than concentration. The hallmark effects of PDRN accumulate over time. A 12-week study by Chung and colleagues (2022) showed progressive improvement in skin parameters throughout the study period, with no plateau at 12 weeks. This suggests that longer-term use yields continued benefits.

Twice-daily application may be superior. Kim and colleagues (2023) compared once-daily versus twice-daily PDRN application in postmenopausal women and found that twice-daily application produced significantly greater improvements in skin elasticity and density. This makes mechanistic sense: nucleotide pools are continuously consumed by cellular processes, so more frequent replenishment sustains higher dNTP levels.

Combine with complementary ingredients. PDRN works through different mechanisms than retinoids, vitamin C, or peptides. These ingredients can be used alongside PDRN without interference, and the combination may be additive or synergistic. The key is to choose products that support different hallmarks of aging: PDRN for genomic stability and mitochondrial function, vitamin C for antioxidant protection and collagen synthesis, retinoids for cellular turnover and collagen stimulation.

Protect your investment with UV protection. UV radiation is the single greatest accelerator of all the hallmarks of aging in skin. No amount of PDRN can compensate for daily UV exposure. A broad-spectrum sunscreen with SPF 50 is non-negotiable in any longevity-focused skincare protocol.

Beyond the Skin: Implications for Whole-Body Longevity

While this article focuses on skin, it is worth noting that the hallmarks of aging are not limited to any single tissue. The same processes of genomic instability, mitochondrial dysfunction, and cellular senescence that drive skin aging also drive aging in every other organ system. PDRN's effects on these hallmarks through topical application may therefore have implications beyond the skin.

Systemic absorption of topically applied PDRN is minimal — the molecules are too large to cross the skin barrier in significant quantities — but the skin itself is an organ with important systemic functions. Healthy skin produces fewer inflammatory mediators that enter the circulation, maintains barrier function that prevents the entry of pathogens and environmental toxins, and preserves thermoregulatory capacity that supports metabolic health.

By improving the health of the skin itself, PDRN may contribute to a reduction in systemic inflammatory burden — the chronic low-grade inflammation that accelerates aging in all tissues. This concept, known as inflammaging, is a well-characterised driver of age-related disease. To the extent that PDRN reduces inflammation in the skin and protects skin barrier function, it may contribute to whole-body health in ways that are just beginning to be appreciated.

References